title: ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X.
abstract: The functional significance of extracellular signal-regulated kinase 2 (ERK2) activation was investigated during shear induced human platelet aggregation (SIPA) in vitro and during shear controlled thrombosis in vivo in intestinal arterioles and venules of wild type (WT) and transgenic (TG) mice with platelet-specific overexpression of human P2X(1) (TG). In SIPA, ERK2 was rapidly phosphorylated during GPIb stimulation, its activation contributing to SIPA for 50%, independently of P2X(1) regulation. Thrombotic occlusion of injured arterioles occurred considerably faster in TG (4.3 +/- 2.3 min) than in WT (38 +/- 8 min) arterioles, but occlusion times in TG (19 +/- 12) and WT (48 +/- 4.5 min) venules differed less. Both the alphabeta-meATP triggered desensitization of platelet P2X(1), as well as P2X(1) antagonism by NF279 or NF449 prolonged mean occlusion to about 75 min in WT and 65 min in TG arterioles, but venular occlusion times were less affected. Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 +/- 10 min) and WT (51 +/- 17) arterioles more than in TG (46 +/- 5 min) and WT (56 +/- 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis. Antagonism of GPIb by a recombinant murine von Willebrand factor (VWF)-A1 fragment prolonged occlusion times to comparable values, ranging from 55 to 58 min, both in TG and WT arterioles and venules. Further inhibition strategies, combining VWF-A1, U0126 and NF449 in WT and TG mice and resulting in occlusion in various time windows, identified that inhibition by VWF-A1 largely abrogated the ERK2 contribution to thrombosis. In conclusion, P2X(1) and ERK2 both participate in shear stress controlled thrombosis, but ERK2 activation is initiated predominantly via GPIb-VWF interactions.
authors.affiliation: Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Oury
authors.forename: K
authors.initials: K
authors.lastname: Daenens
authors.forename: H
authors.initials: H
authors.lastname: Hu
authors.forename: E
authors.initials: E
authors.lastname: Toth-Zsamboki
authors.forename: M
authors.initials: M
authors.lastname: Bryckaert
authors.forename: M F
authors.initials: MF
authors.lastname: Hoylaerts
mesh_terms: D000818:Animals; D001160:Arterioles; D004789:Enzyme Activation; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008822:Mice, Transgenic; D019950:Mitogen-Activated Protein Kinase 1 / Q000097:blood*; D010766:Phosphorylation; D010974:Platelet Aggregation; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000378:metabolism*; D018048:Receptors, Purinergic P2 / Q000097:blood* / Q000235:genetics; D058469:Receptors, Purinergic P2X; D011994:Recombinant Proteins / Q000097:blood / Q000235:genetics; D013314:Stress, Mechanical; D013927:Thrombosis / Q000097:blood* / Q000201:enzymology* / Q000209:etiology; D020246:Venous Thrombosis / Q000097:blood / Q000201:enzymology / Q000209:etiology; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D019038:Platelet Glycoprotein GPIb-IX Complex; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D019950:Mitogen-Activated Protein Kinase 1